|
Removing survivorship bias in a survival model
|
|
2
|
957
|
April 13, 2023
|
|
Imbalance between incident cases and controls
|
|
5
|
911
|
April 11, 2023
|
|
What is the type of my study, case control or retrospective cohort?
|
|
6
|
1018
|
January 27, 2023
|
|
Effectiveness of Paxlovid a retrospective study
|
|
5
|
917
|
January 11, 2023
|
|
Justification of sample size for the generation of a prediction model
|
|
7
|
1643
|
January 11, 2023
|
|
Should we account for competing risk when estimating incidence rate?
|
|
3
|
724
|
January 5, 2023
|
|
Precision-based sample size calculation for one survival curve
|
|
3
|
1195
|
November 16, 2022
|
|
Conceptual question about survival analysis vs logistic regression: when is one more appropriate than the other?
|
|
16
|
13984
|
October 27, 2022
|
|
Background to PFS endpoint
|
|
19
|
6948
|
October 6, 2022
|
|
Method to obtain optimal cut-off point for survival outcomes
|
|
3
|
2525
|
October 1, 2022
|
|
Could cardiovescular risk nomogram be supirior than the Framingham Risk Score? If so, what could be the reasons?
|
|
0
|
774
|
September 20, 2022
|
|
Elastic net model for non-linear relationship?
|
|
2
|
2913
|
July 26, 2022
|
|
Intervention with early survival benefit, questionable long term harm
|
|
8
|
2138
|
May 26, 2022
|
|
Schoenfeld Residuals
|
|
1
|
2335
|
May 23, 2022
|
|
Comparing non-nested models on the same data
|
|
4
|
3893
|
May 13, 2022
|
|
Should I impute person-time before conducting proportional hazards analysis?
|
|
7
|
2058
|
May 8, 2022
|
|
Stratification on a variable involved in an interaction term
|
|
3
|
1691
|
May 4, 2022
|
|
Validation of cox model
|
|
4
|
4867
|
May 2, 2022
|
|
Cutpoint for Estimation of Prognostic value of a continuous Marker
|
|
5
|
2412
|
May 2, 2022
|
|
How should I compare crossing survival curves?
|
|
5
|
4471
|
April 28, 2022
|
|
Is logistic regression or survival analysis most appropriate in this case?
|
|
1
|
1726
|
April 28, 2022
|
|
Statistical power estimation for a time-dependent covariate in Cox (proportional hazards) regression
|
|
0
|
1511
|
April 19, 2022
|
|
Propensity score weighting and competing risks
|
|
2
|
2586
|
March 30, 2022
|
|
How to calculate number of events in each treatment arm given hazard ratio and CI?
|
|
2
|
2441
|
March 6, 2022
|
|
RMS Case Study in Cox Regression
|
|
1
|
15293
|
September 17, 2021
|
|
How to use RCS in mixed effects cox regression
|
|
3
|
4139
|
December 10, 2021
|
|
Kaplan-Meier: SE for absolute difference in time-point survival
|
|
13
|
4371
|
October 30, 2021
|
|
How can I determined the best cutoff for survival ROC
|
|
1
|
2345
|
October 10, 2021
|
|
First RCT of Lopinavir–Ritonavir on SARS-CoV2
|
|
38
|
17390
|
October 8, 2021
|
|
What is the best way to establish correlation between two time-to-event analysis?
|
|
6
|
3815
|
September 13, 2021
|